Monte Rosa Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Monte Rosa Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-9.4%
Buyback Yield
| Total Shareholder Yield | -9.4% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts
Nov 12
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Oct 28We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Sep 23Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if GLUE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GLUE's dividend payments have been increasing.
Dividend Yield vs Market
| Monte Rosa Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GLUE) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (GLUE) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate GLUE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GLUE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate GLUE's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GLUE has not reported any payouts.